Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SL1002

Phase 3Small molecule

SSaol Therapeutics Inc

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Osteoarthritis Knee PainRecruiting

Osteoarthritis Knee PainPhase 3

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Osteoarthritis Knee Pain

NCT07226258

Clinical

Trials by Indication[1]

Osteoarthritis Knee Pain1 trial

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 Injectable for the Treatment of Knee Pain in Patients With Osteoarthritis of the Knee

Recruiting·SSaol Therapeutics Inc·Phase 3·NCT07226258·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SL1002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SL1002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SL1002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Saol Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSaol Therapeutics Inc

Related News